-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cinda Biopharmaceuticals, a biopharmaceutical company dedicated to the research and development, production and sales of innovative drugs for the treatment of tumors, autoimmunity, metabolism, ophthalmic diseases and other major diseases, announced that its world's first ophthalmic anti-VEGF-complement dual target drug ( Research and development code: IBI302) Phase II clinical study completed the first patient administration
.
This study is a randomized, double-blind, multi-center, randomized, double-blind, multi-centered study in subjects with active subfoveal or parafoveal choroidal neovascularization secondary to neovascular age-related macular degeneration (nAMD) An activity-controlled phase II clinical study.
The main purpose of the study is to evaluate the effectiveness and safety of IBI302 dual-target drugs in the treatment of nAMD
.
Anti-VEGF drugs have become the standard treatment for nAMD: Based on the inhibition of VEGF, the vision and ocular anatomy of most patients can be significantly improved
.
However, most single-target anti-VEGF drugs also have some problems, such as the gradual loss of visual benefits after long-term medication and the appearance of retinal fibrosis or retinal atrophy in the macular area
Professor Sun Xiaodong, Shanghai First People’s Hospital affiliated to Shanghai Jiaotong University, said: “At present, antibody drugs targeting VEGF-A have become the first-line treatment for neovascular fundus disease, but the two targets of VEGF and complement The development of specific fusion protein drugs is still a global blank in similar clinical studies.
As a global innovative drug for the treatment of fundus diseases, the results of single and multiple-dose clinical studies that have completed IBI302 suggest that its safety is good and improved The efficacy of vision and retinal thickness is clear
.
The Phase II clinical study will explore its efficacy against macular atrophy and retinal fibrosis.
It is expected to break through the limitations of existing drugs and provide brand-new treatment options to benefit the majority of patients
Dr.
Qian Lei, Executive Director of the Medical Science and Strategic Special Diseases Department of Cinda Biopharmaceutical Group, said: "IBI302 is the world's first anti-VEGF-complement dual-target drug independently developed by Cinda Biopharmaceuticals.
It can block VEGF and target complement at the same time.
The activation of the system has been supported
by a major new drug project of the Ministry of Science and Technology as a category 1 new drug.
IBI302 aims to provide more targeted treatment and intervention from the perspective of the pathogenesis of nAMD by adding additional targets
